FoRx Therapeutics is focused on developing innovative compounds aimed at treating cancer by targeting key molecular mechanisms associated with DNA replication stress. The company is pioneering a novel approach that seeks to drug specific targets involved in the repair of collapsed DNA replication forks, which are critical for maintaining genomic stability. This strategy is rooted in the understanding of DNA Damage Response pathways, an area where the team has over two decades of expertise. The scientific foundation of FoRx is bolstered by a diverse team of professionals with backgrounds in cancer biology, genomics, biochemistry, and medicinal chemistry, all contributing to the advancement of small molecule drug discovery.

Located in Basel, Switzerland, a prominent center for biotechnology and pharmaceuticals, FoRx Therapeutics is well-positioned to leverage its scientific knowledge and industry connections. The company’s pipeline reflects its commitment to developing first-in-class anticancer drugs that address unmet medical needs by focusing on the intricacies of DNA replication stress. By concentrating on these molecular targets, FoRx aims to create effective therapies that can improve outcomes for cancer patients, showcasing its dedication to innovation in cancer treatment.

Switzerland

FoRx Therapeutics is a recently incorporated privately-held company aiming to develop first-in-class compounds for cancer treatment.

FoRx Therapeutics

Company Details